Axia Biopharma Founded
ABOUT US
About us
Our mission is clear: to deliver high quality essential medications to communities worldwide through integrity, reliability, and manufacturing excellence.
Axia BioPharma unites advanced pharmaceutical manufacturing with digital innovation to strengthen access, transparency, and trust across the global supply chain.
It is astonishing that in today’s time, there are many communities throughout the world that lack access to quality essential medications.
- Access built into our operating model to support consistent global availability.
- Transparency, Digital Traceability, and product verification designed to reinforce confidence at every stage.
- Manufacturing quality aligned with the highest international standards.
WHAT WE DO
Axia BioPharma manufactures high quality essential medicines to support global access across key therapeutic areas, including Cardiovascular Disease, Diabetes Disease, Infectious Diseases, Gastrointestinal Disease, and Pain Management.
These therapeutic categories represent a significant portion of the global disease burden, yet access to consistent, quality-assured medications remains limited in many regions. Axia BioPharma is focused on addressing these gaps through reliable manufacturing, quality driven processes, and scalable production capabilities.
In addition to our core portfolio, Axia BioPharma has the capability to develop and manufacture additional therapeutic classes upon request, in alignment with regulatory requirements and partner needs.
Timeline / Our Story
Patent Cliff Wave: Major Pharmaceutical Companies’ medication patents expired (Lipitor, Plavix, Advair) creating an enormous generic manufacturing opportunity
Manufacturing Partner Obtains WHO-GMP Certifications
Global Pandemic increases the Axia Lyfe programs to numerous communities throughout the world
2007
A strategic manufacturing partner begins pharmaceutical operations, establishing the foundation for quality driven production.
2011-2015
The global patent cliff (Lipitor, Plavix, Advair) significantly expands access to generic medicines, creating new opportunities for scalable, high quality pharmaceutical manufacturing.
2018
Our manufacturing partner achieves WHO–GMP certification, reinforcing compliance with internationally recognized quality standards.
2020
The global pandemic accelerates the expansion of Axia Lyfe programs, supporting access to essential medications, supplies, and meals across multiple international communities.
2025
Axia BioPharma continues to scale manufacturing, technology integration, and global operations to support sustainable access to essential medicines worldwide.
Our Team
GLOBAL PRESENCE
Global Headquarters: Dubai, UAE
Dubai, UAE
London, UK
Miami, USA
Dar es Salaam, Tanzania
Delhi, India
Jakarta, Indonesia
